

1 differentiate into hypertrophic chondrocytes, which produce alkaline phosphatase and
2 type X collagen. At the terminal stage of endochondral ossification, the cartilage
3 matrix becomes mineralized and is invaded by blood vessels; and then these
4 hypertrophic chondrocytes are thought to undergo apoptosis. Thus, through this
5 process, cartilage is replaced by bone (Nakanishi et al., 1997; Takigawa et al., 2003).

6 In our series of studies, we have uncovered critical roles of CCN2 (also known as
7 CTGF; connective tissue growth factor) in endochondral ossification (Ivkovic et al.,
8 2003; Kubota and Takigawa, 2011; Nakanishi et al., 1997; Nakanishi et al., 2000;
9 Nishida et al., 2002; Perbal and Takigawa, 2005; Takigawa et al., 2003) and
10 regeneration of articular cartilage (Nishida et al., 2004). Interestingly, in vivo, CCN2
11 molecules are distributed in a layer different from that containing the *Ccn2*
12 mRNA-positive cells. Namely, whereas the chondrocytes expressing the mRNA of the
13 *Ccn2* gene are detected in the prehypertrophic chondrocytes, the CCN2 protein itself is
14 broadly detected from the prehypertrophic zone to the hypertrophic chondrocyte one
15 (Oka et al., 2007). Here, it should be noted that CCN2 is one of the ligands of LRP1,
16 which mediates intracellular protein transport (Gao and Brigstock, 2003; Perbal, 2004;
17 Segarini et al., 2001; Yang et al., 2004).

18 We hypothesized that the difference in the distribution of *Ccn2* mRNA expression
19 and CCN2 protein in vivo was caused by the function of LRP1 in CCN2 protein
20 trafficking. In this study, we for the first time show that LRP1 induces CCN2
21 transcytosis through chondrocytes in vitro.

22

23 **Results**

24 **Effect of *LRP1* knockdown on CCN2 association with chondrocytic cells**

25 Firstly, to examine whether LRP1 participates in associating CCN2 with chondrocytes
26 or not, we performed RNAi experiments to knockdown *LRP1* in HCS-2/8 cells, a
27 human chondrocytic cell line, as previously performed (Kawata et al., 2010). We

1 confirmed that the production of LRP1 protein was substantially knocked down by
2 si-1163 and si-13157 (Fig. 1). We added a recombinant CCN2 with a Flag tag at the
3 N-terminus to the control/ *LRP1* knockdown HCS-2/8 cells, and then collected the cells
4 after 1 hour and performed immunoblotting by using anti-Flag tag antibody. As a
5 result, the bound/ incorporated amount of recombinant CCN2 was decreased in the
6 *LRP1* knockdown HCS-2/8 cells compared with that in the control cells (Fig. 1). The
7 result of immunoblotting with anti-His tag antibody recognizing a 6xHis tag fused to the
8 CCN2 C-terminus was similar to that obtained by using the anti-Flag tag antibody (Fig.
9 1). These results indicate that LRP1 participated in associating CCN2 with
10 chondrocytes.

11

12 **Effect of clathrin inhibition on CCN2 association with chondrocytic cells**

13 Secondly, to examine whether CCN2 association with chondrocytes depend on clathrin
14 or not, we evaluated the effect of endocytosis inhibitors. Namely, we added a
15 recombinant CCN2 with a Flag tag at the N-terminus to the HCS-2/8 cells pretreated
16 either with a clathrin-dependent endocytosis inhibitor, chlorpromazine or a
17 caveolin-dependent endocytosis inhibitor, M β CD and then collected the cells after 1
18 hour and performed immunoblotting by using the anti-Flag tag antibody. As a result,
19 the bound/ incorporated amount of recombinant CCN2 was decreased in the HCS-2/8
20 cells pretreated with chlorpromazine compared with that in the control cells with vehicle
21 only (Fig. 2A). The result of immunoblotting with anti-His tag antibody recognizing
22 the C-terminal 6xHis tag was comparable to that obtained with the anti-Flag tag
23 antibody (Fig. 2A). In contrast, in the HCS-2/8 cells pretreated with M β CD, the
24 bound/ incorporated amount of recombinant CCN2 was unchanged compared with that
25 in the control cells (Fig. 2B). These results indicate that association of CCN2 with
26 chondrocytes is dependent on clathrin.

27

1 **Intracellular destination of CCN2 taken up into HCS-2/8 cells**

2 Subsequently, we added recombinant human CCN2 (rhCCN2) and chased the fate after
3 the application onto HCS-2/8 cells. In fact, exogenously added rhCCN2 and
4 endogenous LRP1 were also partially co-localized inside of the HCS-2/8 cells (Fig. 2C,
5 D). This result again suggests the contribution of LRP1 in the endocytotic
6 incorporation of CCN2. Excluding the signals from nascent CCN2 in exosomes on the
7 way to secretion, we chased the fate of exogenous CCN2 after internalization by
8 anti-Flag antibody. As confirmed by double-staining with the organelle-specific
9 markers, incorporated CCN2 was directed to clathrin (Fig. 2E, F), early (Fig. 2G, H) and
10 recycling endosomes (Fig. 2I, J). Particularly, exogenously added rhCCN2 and, the
11 recycling endosomes marker were predominantly co-localized in HCS-2/8 cells (Fig. 2I,
12 J). Therefore, CCN2, which was internalized in HCS-2/8 cells, was directed to recycle
13 out of the cells toward any direction, following partially the pathway directed by LRP1.

14

15 **Effect of LRP1 on CCN2 transcytosis in chondrocytes**

16 We considered that the broad localization of CCN2 protein from the prehypertrophic
17 zone to the hypertrophic one of growth plate cartilage is possibly realized by
18 LRP1-mediated transcytosis of this protein from the chondrocytes expressing *ccn2* in
19 the prehypertrophic zone. To test the validity of this hypothesis, we performed a
20 transcytosis assay using CCN2 with/ without an LRP1 antagonist, i.e., LRP-associated
21 protein 1 (LRPAP1)/ receptor-associated protein (RAP). After the addition of
22 exogenous CCN2 having an N-terminal Flag tag to the cells in the upper transcytosis
23 chamber (Fig. 3A), the exogenous full-length CCN2 was detected in cell lysates by
24 using anti-Flag tag antibody (Fig. 3B). Moreover, the result of immunoblotting with
25 anti-His tag antibody that recognizing a 6xHis tag fused to the CCN2 C-terminus was
26 similar to that obtained with by using the anti-Flag tag antibody (Fig. 3B). These
27 signals were decreased by LRPAP1 (Fig. 3B). Results similar to those found with the

1 cell lysate were obtained with the medium in the lower chamber (Fig. 3C), which
2 indicates the functional involvement of LRP1 and rules out the possibility of major
3 leakage through the uncovered part of the membrane. Since we basically use an
4 *Escherichia coli* (*E. coli*) derived CCN2, we repeated the same analysis with another
5 recombinant CCN2 from HeLa cells, in order to rule out the possibility of the
6 contamination of *E. coli* components therein. As a result, the exogenous biotin-labeled
7 full-length CCN2 was detected in cell lysates by using horse radish peroxidase (HRP)
8 conjugated avidin, which was inhibited by LRPAP1 (Fig. 3D). Results similar to those
9 found with the cell lysate were obtained with the medium in the lower chamber (Fig.
10 3E). These results clearly indicate that CCN2 is transcytosed, as well as bound/
11 incorporated in chondrocytes mediated by LRP1.

12

13 **Effect of hypoxia on the levels of LRP1 mRNA and protein in HCS-2/8 cells**

14 Cartilage is an avascular tissue; therefore, it has been assumed that the low oxygen
15 partial pressure in the chondrocytic growth plate imposes energetic limitations on the
16 cells as they evolve from a proliferative to a terminally differentiated state (Rajpurohit
17 et al., 1996). Suspecting the contribution of the oxygen pressure gradient to the
18 hypertrophic layer-specific localization of CCN2, we investigated transcytosis of CCN2
19 by LRP1 under hypoxic conditions. Firstly, we examined the levels of *LRP1* mRNA
20 expression and production of LRP1 protein under the hypoxic condition. Exposure to
21 hypoxia resulted in a time-dependent increase in *LRP1* mRNA expression level (Fig.
22 4A). Moreover, the production level of LRP1 protein was increased under hypoxic
23 condition as well (Fig. 4B). Consistent with previous reports (Semenza and Wang,
24 1992; Shimo et al., 2001), the production level of CCN2 and HIF1 α protein was also
25 increased under hypoxic condition (Fig. 4B). Thus, to determine whether HIF1 α
26 mediates the hypoxia-induced LRP1 and CCN2 production, we examined the effect of
27 the antisense HIF1 α oligonucleotides on LRP1 and CCN2 production, respectively,

1 under hypoxic condition. Cultured cells in 5% O₂ with antisense oligonucleotides
2 against HIF1 α (but not with sense oligonucleotide-treated) abolished LRP1, CCN2 as
3 well as HIF1 α induction (Fig. 4C), but β -Actin was unaffected (Fig. 4C). Decreased
4 CCN2 by HIF1 α downregulation agrees with the results of a previous study (Hong et al.,
5 2006). More importantly, these data indicate that HIF1 α regulates not only CCN2 but
6 also LRP1 production under hypoxic condition. Additionally, these results agree with
7 the results of a previous study, in which the level of LRP1 was found to be drastically
8 decreased in the hypertrophic zone of the cartilage near the bone marrow (Kawata et al.,
9 2006).

10

11 **Effect of hypoxia on CCN2 transcytosis in chondrocytes**

12 Secondly, we evaluated the effect of hypoxia on actual CCN2 transport in the same
13 experimental system using the Transwell. As a result of immunoblotting with
14 anti-Flag or His tag antibody, the exogenous CCN2 in the cell lysate was increased
15 under the hypoxic condition compared with the signals under the normoxic condition
16 (Fig. 5A). In the medium in the lower chamber, results similar to those for the cell
17 lysate were obtained (Fig. 5B). In both cases these signals were decreased by LRPAP1,
18 again confirming the functional involvement of LRP1 (Fig. 5). These results indicate
19 that transcytosis of CCN2 in chondrocytes by LRP1 was increased under the hypoxic
20 condition compared with that under the normoxic condition.

21

22 **Higher expression and production levels of LRPAP1 in the chondrocytic cell line**

23 We formerly reported that the LRP1 levels are higher in HCS-2/8 cells than in other
24 types of cells (Kawata et al., 2006). Based on this finding, we next compared
25 expression and production levels of the LRP1 antagonist LRPAP1 in the chondrocytic
26 HCS-2/8 cells with those in the other cell lines. LRP1 and LRPAP1 were analyzed
27 comparatively in HCS-2/8 cells, breast cancer-derived MDA-MD-231 cells (MDA-231),

1 and cervical carcinoma-derived HeLa cells by use of real-time RT-PCR and
2 immunoblotting. As a result, the expression level of *LRP1* was certainly higher in
3 HCS-2/8 cells than in HeLa and MDA-231 cells, as previously reported (Kawata et al.,
4 2006). Similarly, the mRNA level of *LRPAP1* was higher in the HCS-2/8 cells than in
5 the other cells (Fig. 6A). Furthermore, although LRPAP1 protein was detected in all of
6 the cell lines tested, it was more abundant in HCS-2/8 cells than in HeLa and MDA-231
7 cells (Fig. 6B). This result indicates that LRPAP1 was specifically induced in
8 chondrocytic HCS-2/8 cells.

10 **Distribution of LRPAP1 in growth-plate cartilage in vivo**

11 Next, to investigate the production of LRPAP1 in growth-plate cartilage, we performed
12 immunostaining analysis using anti-LRPAP1 antibody and tibial sections prepared from
13 mice. As a result, LRPAP1 was clearly detected, particularly in resting chondrocytes,
14 where CCN2 was absent (Fig. 7A). We formerly reported that LRP1 is present in the
15 growth-plate cartilage, but is drastically decreased along the hypertrophic zone of the
16 cartilage (Kawata et al., 2006). Therefore, LRP1-mediated transcytosis was
17 supposedly suppressed by LRPAP1 in resting chondrocytes.

19 **Changes in the expression of *lrpap1* mRNA in chondrocytes at various 20 differentiation stages in vitro**

21 Following the in vivo analysis, we analyzed the changes in the levels of *lrpap1* mRNA
22 in chondrocytes during differentiation in vitro. To do this, we employed an established
23 differentiation system using primary chicken chondrocytes (Iwamoto et al., 1995). For
24 the evaluation of gene expression, real-time quantitative RT-PCR was performed (Fig.
25 7B). We initially confirmed that lower sternum (LS), upper sternal peripheral (USP)
26 and upper sternal core (USC) cells represented resting, proliferating, and hypertrophic
27 chondrocytes, respectively. Indeed, the *col2a1* mRNA level was the highest in the LS

1 cells, whereas the *col10a1* mRNA level was the highest in the USC cells. Moreover,
2 the *alp* mRNA level was lower in the LS cells than in the other cells. Under this
3 condition, the expression of *lrpap1* mRNA was the highest in LS cells, confirming
4 strong distribution of LRPAP1 protein in resting chondrocytes in vivo.

5

6 **Discussion**

7 CCN2 acts in a harmonized manner on all cells involved in the promotion of
8 endochondral ossification. In the growth-plate in vivo, CCN2 protein is distributed in
9 a pattern different from that of its mRNA. Namely, whereas *Ccn2* mRNA expression
10 is found in the prehypertrophic chondrocytes, CCN2 protein is broadly detected from
11 the prehypertrophic to the hypertrophic zone (Oka et al., 2007). This broad
12 distribution enables CCN2 to contact all the target cells, and thus is of critical
13 importance. Here, we should note that CCN2 is one of the ligands of LRP1 (Gao and
14 Brigstock, 2003; Perbal, 2004; Segarini et al., 2001; Yang et al., 2004). We considered
15 that such a distribution of CCN2 protein was realized by LRP1-mediated transcytosis.
16 To test the validity of this hypothesis, we performed this study and found that not only
17 CCN2 binding/ incorporation but also CCN2 transcytosis was indeed mediated by LRP1
18 (Figs. 3, 5).

19 Since the growth-plate is an avascular tissue, it has been assumed that the low oxygen
20 partial pressure in the chondrocytic growth-plate imposes energetic limitations on the
21 cells as they differentiate from a proliferative to a terminally differentiated state
22 (Rajpurohit et al., 1996). Therefore, mimicking such in vivo conditions, we examined
23 the levels of *LRP1* mRNA expression and LRP1 protein production under the hypoxic
24 condition in vitro. As a result, exposure to hypoxia increased both mRNA expression
25 and protein production levels of LRP1 (Fig. 4). These results support a previous
26 finding that the level of LRP1 is drastically decreased along the hypertrophic zone of
27 the cartilage (Kawata et al., 2006). Moreover, in a previous study, increased mRNA

1 expression of the *lrp1* gene in carcinoma-derived cells under hypoxia was demonstrated
2 as well (Koong et al., 2000). Consistent with these findings, transcytosis of CCN2 by
3 LRP1 was increased under the hypoxic condition compared with that under the
4 normoxic one in chondrocytes (Fig. 5). Thus, we propose that the distribution of
5 CCN2 in growth-plate cartilage is controlled possibly by LRP1 regulated by hypoxia
6 (Fig. 8).

7 Although cartilage is avascular, the cartilage matrix is invaded by blood vessels at the
8 terminal stage of endochondral ossification (Nakanishi et al., 1997; Takigawa et al.,
9 2003). Therefore, the level of the oxygen tension might be different according to the
10 difference in the quantity of the oxygen supply between the entirely avascular layer of
11 resting chondrocytes and layer of hypertrophic chondrocytes that is invaded by blood
12 vessels. According to such an oxygen tension gradient, LRP1 production would be
13 suspected to be repressed in the late hypertrophic layer, as described previously, which
14 may prevent the flow-through of CCN2 into the bone marrow.

15 Finally, we should comment on the distribution of LRPAP1, the natural LRP1
16 antagonist, in the growth plate. We formerly reported that the LRP1 levels were higher
17 in HCS-2/8 cells than in the other cells (Kawata et al., 2006). As was shown here, the
18 mRNA and protein levels of LRPAP1 were also higher in HCS-2/8 cells than in HeLa
19 and MDA-231 cells (Fig. 6). These results indicate that LRPAP1 was specifically
20 induced in chondrocytes, and concomitant expression and production of LRP1 and
21 LRPAP1 suggests a particular role of LRPAP1 in the endocytotic pathway in
22 chondrocytes. Importantly, LRPAP1 was detected particularly in resting chondrocytes,
23 where CCN2 was absent (Fig. 7). Thus, in the growth-plate cartilage, CCN2 produced
24 in the prehypertrophic chondrocyte layer may not be transcytosed to the resting
25 chondrocyte layer, being prevented by the higher level of LRPAP1. Collectively,
26 localization of CCN2 in the growth plate would supposedly be maintained by LRP1
27 under the interaction with LRPAP1 and the hypoxic gradient therein (Fig. 8).

1

2 **Materials and Methods**

3 **Antibodies and reagents**

4 For immunoblotting and/ or immunofluorescence microscopy, anti-FLAG M2
5 MONOCLONAL (Sigma Aldrich, St. Louis, MO), anti-6-His (BETHYL, Montgomery,
6 TX), monoclonal 5A6 (Progen, Heidelberg, Germany) recognizing the 85-kDa LRP1
7 light chain, a rabbit polyclonal H-80 antibody (Santa Cruz Biotech, Santa Cruz, CA),
8 which recognizes amino acids 206–285 of LRP1, anti- β -Actin AC-74 (Sigma Aldrich),
9 anti-Clathrin Heavy Chain P1663 (Cell Signaling Technology, Inc. Danvers, MA),
10 anti-EEA1 (Cell Signaling Technology, Inc.), anti-Rab11 (C-19; Santa Cruz Biotech),
11 anti-CTGF ab6992 (abcam, Cambridge, England), anti-Hypoxia Inducible Factor (HIF)
12 1 α clone H1 α 67 (Millipore, Billerica, MA), and anti-LRPAP1 rabbit monoclonal
13 (Epitomics, Inc., Burlingame, CA) antibodies were employed. As secondary
14 antibodies, horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody was
15 purchased from GE Healthcare UK Ltd (Buckinghamshire, England), HRP-conjugated
16 anti-rabbit IgG antibody, from BETHYL; and Alexa Fluor 488 goat anti-rabbit IgG,
17 Alexa Fluor 568 goat anti-mouse IgG, Alexa Fluor 488 donkey anti-goat IgG, from
18 Molecular Probes (Eugene, OR). Streptavidin HRP conjugate was purchased from
19 Zymed Laboratories (San Francisco, CA). Chlorpromazine and
20 methyl- β -cyclodextrin (M β CD) were purchased from LKT Laboratories, Inc. (St. Paul,
21 MN) and Sigma Aldrich, respectively.

22

23 **Cells**

24 HCS-2/8 cells (a human chondrocytic cell line; (Takigawa et al., 1991; Takigawa et
25 al., 1989), HeLa (a human cervical cancer cell line), and MDA-MB-231 (MDA-231; a
26 human breast cancer cell line) were cultured in Dulbecco's modification of minimum
27 essential medium (D-MEM) containing 10% fetal bovine serum (FBS). The cells were

1 cultured at 37°C in humidified air with 5% CO₂. Hypoxia experiments were
2 performed for the desired times in a humidified triple gas model BL-40M incubator
3 (BIO-LABO, Tokyo, Japan) calibrated to deliver 5% CO₂, 5% O₂, and 90% N₂ at 37°C
4 for 8-48 h. Primary chicken chondrocytes were isolated from the caudal one-third
5 portions (LS) of the sterna, the peripheral regions (USP), and central core regions
6 (USC) of the cephalic portions of the sterna of day-17 chick embryos by using the
7 method described earlier (Iwamoto et al., 1995).

8

9 **LRP1 siRNA transfection**

10 To knockdown LRP1 protein production, we used RNA interference technology.
11 Two designed pairs of RNA oligoduplexes targeting human *LRP1* (gene accession No.
12 NM_002332) were purchased from Hokkaido System Science Co., Ltd. (Sapporo,
13 Japan). The target nucleotide sequences of those oligoduplexes were 5'-UGG ACU
14 AUA UUG AAG UGG UGG ACU AAG-3' and 5'-CCU GUA CCA UGA ACA GCA
15 AAA UGA UAG-3'. The former was termed LRP-1163; and the latter, LRP-13157.
16 A nonspecific oligoduplex (nonsilencing control, targeting 5'-UUA GGG GAU AAG
17 UAC GGU UGA AUC UAG-3') was used as a negative control at the same final
18 concentrations as used for the human LRP1-targeting RNA duplexes. Prior to
19 transfection, the cells were transferred to each well in 6-well plates (density: 4×10^5
20 cells/well). Transient transfection with a 70 nM concentration of siRNA was
21 performed by using siPORT NeoFX™ Transfection Agent (Applied Biosystem, Foster
22 City, CA) according to the manufacturer's protocol. At 24 h after the transfection, the
23 medium was exchanged for fresh medium; and the cells were then cultured for another
24 48 h.

25

26 **Expression and purification of full-length recombinant human CCN2 (rhCCN2)**

27 Expression and purification of full-length rhCCN2 protein derived from HeLa cells or

1 E. coli were carried out, as described previously (Aoyama et al., 2009; Nakanishi et
2 al., 2000).

3

4 **Association and transcytosis assay of CCN2**

5 The HCS-2/8 cells were washed 3 times on ice with cold phosphate-buffered saline
6 (PBS), and LRPAP1 were added the cells. After 15 minutes, the cells were allowed to
7 association with CCN2 in serum free D-MEM containing 2 µg/ml recombinant CCN2 at
8 37 °C for 1 h. For inhibitor assays, prior to addition of CCN2, HCS-2/8 cells were
9 preincubated for 5 min at 37°C in medium lacking FBS and with 5 µM chlorpromazine
10 or 3 mM MβCD that specifically inhibited endocytic pathways. Then, the cells were
11 washed 3 times on ice with cold PBS. After that, cell layers (total binding samples)
12 were harvested in 100 µl of lysis buffer (20 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1
13 mM EDTA, 1% Triton X-100, 1 mM Na₃VO₄, 5% glycerol, 40 mM ammonium
14 molybdate, and 1 mM phenylmethylsulfonyl fluoride). For the transcytosis assays of
15 CCN2, HCS-2/8 cells were seeded in Transwell chambers with the pore size of 0.4 µm
16 (Millipore, Billerica, MA), which had been inserted into 6-well culture plates (density: 6
17 × 10⁵ cells/well) containing D-MEM supplemented with 10% FBS and incubated at
18 37°C for 1 week. The cells were washed 3 times on ice with cold PBS and then
19 allowed to associate with CCN2 at 37°C for 1 h in serum-free D-MEM containing 2
20 µg/ml recombinant CCN2. All cells were subsequently washed 3 times on ice with
21 cold PBS. Cell lysates (total binding samples) on upper chambers were harvested in
22 100 µl of lysis buffer. The medium in the lower chamber (transcytosis sample) was
23 harvested, and then anti-FLAG® M2 affinity gel freezer-safe (Sigma Aldrich) or
24 Ni-NTA (Ni²⁺-nitrilotriacetate)-agarose gel (Qiagen, Hilden, Germany) was added to it,
25 which mixture was subsequently incubated for 2 h with gentle rotation to capture the
26 Flag or His-tagged protein in the medium. After the removal of the supernatant, then
27 PBS and 1× SDS sample buffer (50 mM Tris-HCl [pH6.8], 2% SDS, 5% glycerol, 2%

1 bromphenol blue) with 2-mercaptoethanol was added to the gel to elute the bound
2 proteins.

4 **Immunoblot analysis**

5 HCS-2/8 cells were lysed in the lysis buffer. The lysate diluted in 1× SDS sample
6 buffer with or without 2-mercaptoethanol was boiled for 3 min, and was then subjected
7 to SDS-PAGE in 9% or 12% polyacrylamide gels. Proteins were transferred onto
8 polyvinylidene difluoride (PVDF) membranes with a blotting apparatus. The
9 membranes were then incubated for 1 h in a blocking buffer (3% dry non-fat milk in
10 PBS) and subsequently incubated overnight with anti-Flag (1:1000), anti-GAPDH
11 (1:100), anti-6-His (1:1000), anti-LRP1 5A6 (1:100), anti-β-Actin (1:5000), anti-CCN2
12 (1:1000), anti-HIF1α (1:1000), anti-LRPAP1 (1:500) antibody, or Streptavidin HRP
13 conjugate (1:2000) in the blocking buffer. Next, the membrane was washed 5 times in
14 PBS and then incubated for 2 h with HRP-conjugated anti-mouse (1:5000) or anti-rabbit
15 (1:5000) IgG in the blocking buffer. After extensive washes with PBS,
16 immunoreactive proteins were detected by using an ECL Western Blotting Detection
17 System (Amersham Biosciences, Piscataway, NJ).

19 **Immunocytochemistry**

20 HCS-2/8 cells were cultured on glass coverslips, fixed in 4% paraformaldehyde (w/v)
21 in a phosphate buffer (PB) for 15 min and permeabilized with 0.2% Triton X-100 for 15
22 min. Primary anti-LRP1 H-80 (1:40), anti-Flag (1:200), anti-clathrin (1:300),
23 anti-EEA1 (1:100), and anti-Rab11 C-19 (1:40), antibodies were used for detection.
24 Alexa Fluor-labeled secondary antibodies were also utilized at 1:500.

26 **Confocal laser-scanning microscopy**

27 Confocal laser microscopy was performed using a ZEISS Confocal Laser Scanning

1 Microscope Model LSM510 (Carl Zeiss, Oberkochen, Germany) belonging to Central
2 Research Laboratory, Okayama University Medical School.

3

4 **Biotin labeled CCN2 protein derived from HeLa cells**

5 CCN2 protein derived from HeLa cells was biotin-labeled by a commercially available
6 kit, following the manufacturer's instructions (Biotin Labeling Kit-NH₂; Dojindo
7 Molecular Technologies, Inc, Kamimashiki-Gun, Japan).

8

9 **RNA extraction and cDNA synthesis**

10 Cells were collected, and total RNA was extracted by following the manufacturer's
11 instructions (RNeasy kit, Qiagen). Total RNA (500 ng) was reverse-transcribed by
12 AMV Reverse Transcriptase (Takara, Ohtsu, Japan) at 42°C for 30 min, according to the
13 manufacturer's protocol.

14

15 **Real-time PCR**

16 Real-time PCR was performed by using TOYOBO SYBR Green PCR Master Mix
17 (TOYOBO, Osaka, Japan) in a LightCycler™ system (Roche, Basel, Switzerland).
18 Reactions were performed in a 10- μ l reaction mixture containing 1 μ l of cDNA, 0.4 μ l
19 of each primer (5 μ M), and 5 μ l of 1 \times SYBR Green master mix. Primer sets and
20 optimized conditions for the PCR of each target are listed in Table 1. Absence of
21 non-specific PCR products was checked by melting curve and electrophoresis analyses.
22 Relative copy numbers were computed based on data obtained with a serial dilution of a
23 representative sample for each target gene.

24

25 **Antisense oligonucleotides**

26 To inhibit the expression of HIF1 α , we prepared an antisense phosphorothioate
27 oligonucleotide (AS-HIF) and a sense oligonucleotide (S-HIF: control) according to the

1 nucleotide sequence of the human HIF1 α gene (Caniggia et al., 2000). The nucleotide
2 sequences of the AS-HIF and S-HIF were 5'-GCCGGCGCCCTCCAT-3' and
3 5'-ATGGAGGGCGCCGGC-3', respectively. These oligonucleotides were added
4 directly to medium in HCS-2/8 cells culture at a concentration of 10 μ M.

5

6 **Animals and preparation of tissue**

7 After Balbc/j mice (2 weeks of age) had been anesthetized with sodium pentobarbital
8 (Nembutal, Abbott laboratories, North Chicago, IL; 25 mg/kg), proximal tibiae were
9 harvested and immersed in 4% paraformaldehyde (w/v) in phosphate buffer (PB: 0.1 M
10 NaH₂PO₄, 0.1 M Na₂HPO₄; pH 7.4) at 4°C overnight. After having been rinsed in
11 PBS, the tibiae were decalcified in 0.5 M EDTA, pH 7.4, at 4°C and then embedded in
12 paraffin wax. The sections were prepared at a thickness of 7 μ m and mounted on
13 silane-coated slides. The Animal Committee of Okayama University approved all of
14 the procedures.

15

16 **Immunohistochemistry**

17 Tibial sections were dewaxed in xylene and rehydrated through a graded series of
18 ethanol to water, blocked in a blocking buffer (5% dry non-fat milk in Tris-buffered
19 saline), and incubated overnight at 4°C with the primary anti-LRPAP1 antibody (1:100)
20 and subsequently with an HRP-conjugated anti-rabbit IgG (1:1000) for 1 h at room
21 temperature. Color development was performed by using 3, 3'-diaminobenzidine
22 tetrachloride (Dojindo, Tokyo, Japan). The sections were also counterstained with
23 hematoxylin and mounted. Control samples were processed with the omission of the
24 primary antibody.

25

26 **Statistics**

27 Data were presented as means \pm standard deviations, and the statistical significance

1 of differences in mean values was assessed by performing Student's unpaired *t*-test.
2 Differences among the mean values were considered significant at a *P* value of <0.05.

3

4 All experiments were repeated at least twice, and similar results were obtained.

5

6 **Acknowledgements**

7 This work was supported by the programs Grants-in-Aid for Scientific Research (S)
8 [to M.T.] and (C) [to S.K.] and Grants-in-Aid for Exploratory Research (to M.T.) from
9 Japan Society for the Promotion of Science; by Grants-in-Aid for Fellows of the
10 Japanese Society for the Promotion of Science (to T.E.); and by grants from the
11 Sumitomo Foundation (to M.T.), Foundation of Sanyo Broadcasting (to S.K.), Terumo
12 Life Science Foundation (to S.K.), and Ryobi Teien Memory Foundation (to K.K.).

13

14 **References**

15 **Aoyama, E., Hattori, T., Hoshijima, M., Araki, D., Nishida, T., Kubota, S.**
16 **and Takigawa, M.** (2009). N-terminal domains of CCN family 2/connective tissue
17 growth factor bind to aggrecan. *Biochem J* **420**, 413-20.

18 **Boucher, P., Gotthardt, M., Li, W. P., Anderson, R. G. and Herz, J.** (2003).
19 LRP: role in vascular wall integrity and protection from atherosclerosis. *Science* **300**,
20 329-32.

21 **Caniggia, I., Mostachfi, H., Winter, J., Gassmann, M., Lye, S. J.,**
22 **Kuliszewski, M. and Post, M.** (2000). Hypoxia-inducible factor-1 mediates the
23 biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). *J*
24 *Clin Invest* **105**, 577-87.

25 **Gao, R. and Brigstock, D. R.** (2003). Low density lipoprotein receptor-related
26 protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth
27 factor (CTGF) in rat activated hepatic stellate cells. *Hepatol Res* **27**, 214-220.

- 1 **Gardai, S. J., Xiao, Y. Q., Dickinson, M., Nick, J. A., Voelker, D. R., Greene,**
2 **K. E. and Henson, P. M.** (2003). By binding SIRPalpha or calreticulin/CD91, lung
3 collectins act as dual function surveillance molecules to suppress or enhance
4 inflammation. *Cell* **115**, 13-23.
- 5 **Hayashi, H., Campenot, R. B., Vance, D. E. and Vance, J. E.** (2007).
6 Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling
7 pathway involving low-density lipoprotein receptor-related protein-1. *J Neurosci* **27**,
8 1933-41.
- 9 **Herz, J.** (2001). The LDL receptor gene family: (un)expected signal
10 transducers in the brain. *Neuron* **29**, 571-81.
- 11 **Herz, J., Clouthier, D. E. and Hammer, R. E.** (1992). LDL receptor-related
12 protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo
13 implantation. *Cell* **71**, 411-21.
- 14 **Herz, J. and Strickland, D. K.** (2001). LRP: a multifunctional scavenger and
15 signaling receptor. *J Clin Invest* **108**, 779-84.
- 16 **Hong, K. H., Yoo, S. A., Kang, S. S., Choi, J. J., Kim, W. U. and Cho, C. S.**
17 (2006). Hypoxia induces expression of connective tissue growth factor in scleroderma
18 skin fibroblasts. *Clin Exp Immunol* **146**, 362-70.
- 19 **Hussain, M. M.** (2001). Structural, biochemical and signaling properties of the
20 low-density lipoprotein receptor gene family. *Front Biosci* **6**, D417-28.
- 21 **Ivkovic, S., Yoon, B. S., Popoff, S. N., Safadi, F. F., Libuda, D. E.,**
22 **Stephenson, R. C., Daluiski, A. and Lyons, K. M.** (2003). Connective tissue growth
23 factor coordinates chondrogenesis and angiogenesis during skeletal development.
24 *Development* **130**, 2779-91.
- 25 **Iwamoto, M., Shimazu, A. and Pacifici, M.** (1995). Regulation of
26 chondrocyte maturation by fibroblast growth factor-2 and parathyroid hormone. *J*
27 *Orthop Res* **13**, 838-45.

- 1 **Kawata, K., Eguchi, T., Kubota, S., Kawaki, H., Oka, M., Minagi, S. and**
2 **Takigawa, M.** (2006). Possible role of LRP1, a CCN2 receptor, in chondrocytes.
3 *Biochem Biophys Res Commun* **345**, 552-9.
- 4 **Kawata, K., Kubota, S., Eguchi, T., Moritani, N. H., Shimo, T., Kondo, S.,**
5 **Nishida, T., Minagi, S. and Takigawa, M.** (2010). Role of the low-density lipoprotein
6 receptor-related protein-1 in regulation of chondrocyte differentiation. *J Cell Physiol*
7 **222**, 138-48.
- 8 **Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L.,**
9 **Koch, C., Evans, S., Ibrahim, H., Le, Q. T., Terris, D. J. et al.** (2000). Candidate
10 genes for the hypoxic tumor phenotype. *Cancer Res* **60**, 883-7.
- 11 **Kubota, S. and Takigawa, M.** (2011). The role of CCN2 in cartilage and bone
12 development. *J Cell Commun Signal* **5**, 209-17.
- 13 **Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E. and Strickland, D. K.**
14 (2008). LDL receptor-related protein 1: unique tissue-specific functions revealed by
15 selective gene knockout studies. *Physiol Rev* **88**, 887-918.
- 16 **May, P. and Herz, J.** (2003). LDL receptor-related proteins in
17 neurodevelopment. *Traffic* **4**, 291-301.
- 18 **Nakanishi, T., Kimura, Y., Tamura, T., Ichikawa, H., Yamaai, Y., Sugimoto,**
19 **T. and Takigawa, M.** (1997). Cloning of a mRNA preferentially expressed in
20 chondrocytes by differential display-PCR from a human chondrocytic cell line that is
21 identical with connective tissue growth factor (CTGF) mRNA. *Biochem Biophys Res*
22 *Commun* **234**, 206-10.
- 23 **Nakanishi, T., Nishida, T., Shimo, T., Kobayashi, K., Kubo, T., Tamatani,**
24 **T., Tezuka, K. and Takigawa, M.** (2000). Effects of CTGF/Hcs24, a product of a
25 hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of
26 chondrocytes in culture. *Endocrinology* **141**, 264-73.
- 27 **Nishida, T., Kubota, S., Kojima, S., Kuboki, T., Nakao, K., Kushibiki, T.,**

- 1 **Tabata, Y. and Takigawa, M.** (2004). Regeneration of defects in articular cartilage in
2 rat knee joints by CCN2 (connective tissue growth factor). *J Bone Miner Res* **19**,
3 1308-19.
- 4 **Nishida, T., Kubota, S., Nakanishi, T., Kuboki, T., Yosimichi, G., Kondo, S.**
5 **and Takigawa, M.** (2002). CTGF/Hcs24, a hypertrophic chondrocyte-specific gene
6 product, stimulates proliferation and differentiation, but not hypertrophy of cultured
7 articular chondrocytes. *J Cell Physiol* **192**, 55-63.
- 8 **Oka, M., Kubota, S., Kondo, S., Eguchi, T., Kuroda, C., Kawata, K.,**
9 **Minagi, S. and Takigawa, M.** (2007). Gene expression and distribution of connective
10 tissue growth factor (CCN2/CTGF) during secondary ossification center formation. *J*
11 *Histochem Cytochem* **55**, 1245-55.
- 12 **Perbal, B.** (2004). CCN proteins: multifunctional signalling regulators. *Lancet*
13 **363**, 62-4.
- 14 **Perbal, B. and Takigawa, M.** (2005). CCN proteins: a new family of cell
15 growth and differentiation regulators. London: Imperial College Press.
- 16 **Rajpurohit, R., Koch, C. J., Tao, Z., Teixeira, C. M. and Shapiro, I. M.**
17 (1996). Adaptation of chondrocytes to low oxygen tension: relationship between
18 hypoxia and cellular metabolism. *J Cell Physiol* **168**, 424-32.
- 19 **Segarini, P. R., Nesbitt, J. E., Li, D., Hays, L. G., Yates, J. R., 3rd and**
20 **Carmichael, D. F.** (2001). The low density lipoprotein receptor-related
21 protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor.
22 *J Biol Chem* **276**, 40659-67.
- 23 **Semenza, G. L. and Wang, G. L.** (1992). A nuclear factor induced by hypoxia
24 via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site
25 required for transcriptional activation. *Mol Cell Biol* **12**, 5447-54.
- 26 **Shimo, T., Kubota, S., Kondo, S., Nakanishi, T., Sasaki, A., Mese, H.,**
27 **Matsumura, T. and Takigawa, M.** (2001). Connective tissue growth factor as a major

1 angiogenic agent that is induced by hypoxia in a human breast cancer cell line. *Cancer*
2 *Lett* **174**, 57-64.

3 **Takigawa, M., Nakanishi, T., Kubota, S. and Nishida, T.** (2003). Role of
4 CTGF/HCS24/ecogenin in skeletal growth control. *J Cell Physiol* **194**, 256-66.

5 **Takigawa, M., Pan, H. O., Kinoshita, A., Tajima, K. and Takano, Y.** (1991).
6 Establishment from a human chondrosarcoma of a new immortal cell line with high
7 tumorigenicity in vivo, which is able to form proteoglycan-rich cartilage-like nodules
8 and to respond to insulin in vitro. *Int J Cancer* **48**, 717-25.

9 **Takigawa, M., Tajima, K., Pan, H. O., Enomoto, M., Kinoshita, A., Suzuki,**
10 **F., Takano, Y. and Mori, Y.** (1989). Establishment of a clonal human chondrosarcoma
11 cell line with cartilage phenotypes. *Cancer Res* **49**, 3996-4002.

12 **Yang, M., Huang, H., Li, J., Li, D. and Wang, H.** (2004). Tyrosine
13 phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK
14 pathway are required for connective tissue growth factor to potentiate myofibroblast
15 differentiation. *Faseb J* **18**, 1920-1.

16 **Zilberberg, A., Yaniv, A. and Gazit, A.** (2004). The low density lipoprotein
17 receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the
18 canonical Wnt signaling pathway. *J Biol Chem* **279**, 17535-42.

19
20

1 **Figure Legends**

2 **Fig. 1. Effect of *LRP1* knockdown on CCN2 association with chondrocytic cells.**

3 Recombinant CCN2 was designed to possess a Flag tag, which was captured or
4 internalized by LRP1 (left panel). Dual-tagged recombinant CCN2 was added to
5 control or *LRP1* knockdown HCS-2/8 cells, the medium was removed after 1 h, and the
6 cellular protein was collected. Immunoblotting was performed by using anti-Flag or
7 His tag antibody. Positions of molecular weight markers (35, 75 kDa) are shown at the
8 right of the images (right panel). NC, non-silencing siRNA as a negative control;
9 si-1163, LRP1 siRNA (target sequence position 1163); si-13157, LRP1 siRNA (target
10 sequence position 13157).

11

12 **Fig. 2. Effect of chlorpromazine on the CCN2 association with chondrocytic cells.**

13 Dual-tagged CCN2 was added to control or chlorpromazine (A) / M β CD (B) -treated
14 HCS-2/8 cells and the cellular protein was collected after 1 h. Immunoblotting was
15 performed by using anti-Flag or anti-His tag antibody. As a result, the
16 bound/incorporated CCN2 was decreased in the chlorpromazine-treated HCS-2/8 cells
17 (A), while it was not in M β CD-treated ones (B). Positions of molecular weight
18 markers (35, 75 kDa) are shown at the right of the images. (C, D) Internalization of the
19 exogenously added rhCCN2 into HCS-2/8 cells and intracellular co-localization with
20 endogenous LRP1. The Flag-tagged CCN2 was added and analyzed by laser-scanning
21 confocal microscopy after 15 minutes. The distribution of LRP1 in HCS-2/8 cells was
22 visualized with an antibody for LRP1 (H-80 for α -subunit). The intracellular CCN2
23 uptake and co-localization with LRP1 was evident. (E-L) Intracellular delivery of
24 exogenously added rhCCN2 into certain organelle of HCS-2/8 cells. Staining of
25 clathrin (E, F), EEA1 (G, H; a marker of early endosomes) or Rab11 (I, J; a marker of
26 recycling endosomes) is shown. The squares in panels C, E, G and I indicate the areas
27 enlarged in the panels D, F, H and J, respectively. Incorporated rhCCN2 was partially